Anti-Human LOXL2 Recombinant Antibody (Simtuzumab) (CAT#: TAB-890)

Recombinant humanized antibody expressed in CHO binding to human LOXL2. Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Formats:
  • Isotype Switching:
  • Fc Engineering:
  • Modalities:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Inhib

Figure 1 Effects of Simtuzumab on normal myofibroblast differentiation and invasion.

Figure 1 Effects of Simtuzumab on normal myofibroblast differentiation and invasion.

Fibroblast cultures derived from normal lung samples were treated with anti-LOXL2 (1, 10, and 50 μg/ml), BIBF1120 (300 nM) and their respective controls in the absence or presence of CpG (10 nM), IL-13 (10 ng/ml) or TGF-β (20 ng/ml).

Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.

Inhib

Figure 2 Effects of Simtuzumab on IPF myofibroblast differentiation and invasion.

Figure 2 Effects of Simtuzumab on IPF myofibroblast differentiation and invasion.

Fibroblast cultures derived from IPF lung samples were treated with anti-LOXL2 (1, 10, and 50 μg/ml), BIBF1120 (300 nM) and their respective controls in the absence or presence of CpG (10 nM), IL-13 (10 ng/ml) or TGF-β (20 ng/ml).

Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.

Agonist

Figure 3 Simtuzumab accelerates cell differentiation in vitro.

Figure 3 Simtuzumab accelerates cell differentiation in vitro.

Explanted lung cells from normal and IPF lung samples were treated with anti-LOXL2 (50 μg/ml), or IgG for 26 days. Media and treatments were replaced 2x/week until day 26.

Espindola, M. S., Habiel, D. M., Coelho, A. L., Mikels-Vigdal, A., & Hogaboam, C. M. (2019). Targeting Lysyl oxidase-like 2 in Idiopathic Pulmonary Fibrosis. bioRxiv, 813907.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • undefined
  • Derivation
  • Humanized
  • Type
  • IgG4 - kappa
  • Species Reactivity
  • Human
  • Applications
  • Inhib, Agonist
  • CAS
  • 1318075-13-6
  • Generic Name
  • Simtuzumab
  • MW
  • 147.5 kDa
  • Related Disease
  • Myelofibrosis

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store at -20°C. Avoid multiple freeze/thaw cycles.

Applications

  • Application Notes
  • The LOXL2 ADCC antibody has been reported in applications of Inhibition, Agonist.
    Inhib: 1, 10, and 50 μg/ml.
    Agonist: 50 μg/ml.

Target

  • Alternative Names
  • Simtuzumab;1318075-13-6;AB0024;GS-6624;LOXL2;lysyl oxidase-like 2;lysyl oxidase homolog 2;WS9 14;lysyl oxidase related 2;lysyl oxidase-like protein 2;lysyl oxidase-related protein 2;lysyl oxidase-related protein WS9-14;LOR2;WS9-14;

Related Resources

  • Biosimilar Overview
Please refer to Simtuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Simtuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Simtuzumab"

Afuco™ Anti-LOXL2 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-890)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human LOXL2. It is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator.
DrugMonitor™ Anti-Simtuzumab Antibody (VS-1224-YC1091)
Simtuzumab has been explored in trials for the treatment of myelofibrosis, pancreatic cancer, colorectal cancer, and idiopathic pulmonary fibrosis. The DrugMonitor™ Anti-Simtuzumab Antibody (VS-1224-YC1091) is an anti-drug antibody (ADA) against Simtuzumab. This drug-based antibody is raised in mice immunized with the Simtuzumab. The anti-Simtuzumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Simtuzumab in samples.

See other products for "LOXL2"

Select a product category from the dropdown menu below to view related products.
Please select product type
Mouse Antibody Products Rabbit Monoclonal Antibody Products ScFv Antibody Products Fab Antibody Products IgG Antibody Products ADCC Enhanced Antibody Products

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for TAB-890. Click the button above to contact us or submit your feedback about this product.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-890, RRID: AB_3112015)

Copy citation

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare